AbbVie

Open: 154.74 Close: 154.04 Change: -0.7

Are you still looking for information about AbbVie Company Inc? An AI summarized it for you.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, Inc, ABBV, Cerevel, Abbvie, share, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

Goldman Sachs upgraded the pharma giant to Buy from Neutral with a 12-month price target of $173. AbbVie currently Up 11 Consecutive Days, on Pace for Longest Winning Streak since December 2021.

Today's News

AbbVie Inc. stock outperforms competitors despite losses on the day. ABBV -0.54% DJIA +0.15% SPX - 0.01% JNJ -1.09% PFE +1.91% Cerevel options trading surge before AbbVie deal news raises eyebrows. Cerevel Therapeutics is a developer of drugs for neurological conditions such as Parkinsons. $100 Invested in AbbVie 10 years ago would be worth this much today. The big drugmaker went on a holiday shopping spree. AbbVie to Host Third-Quarter 2023 Earnings Conference Call on Oct. 04. Abbvie to Present at Morgan Stanley Healthcare Conference. AbbVie Inc (ABBV) stock has gained 0.48% while the S&P 500 is higher by 0.07% as of 12:19 PM on Wednesday, Dec 13. Abbvie, Inc. (ABbV) has announced U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) updates. AbbVie Pharmaceutical Manufacturing North Chicago, Illinois, has 53,410 employees. The company is focused on creating medicines and solutions that put impact first. By acquiring Cerevel, AbbVie will augment its neuroscience pipeline with multiple clinical-stage and preclinical drug candidates. AbbVie currently Up 11 Consecutive Days, on Pace for Longest Winning Streak Since December 2021. The company also started offering four weeks of paid caregiver leave in 2022. AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share in cash, the companies said Thursday in a statement. Abbvie shares fell 0.4% in trading before US markets opened on Thursday. Goldman Sachs upgraded the pharma giant to Buy from Neutral with a 12-month price target of $173. Goldman Sachs analyst Shibutani argues that AbbVie ( ABBV) is positioned to generate an overall company growth profile Senior Scientist I- Strain Engineering at ABBVIE seeks a highly skilled and experienced senior scientist with the expertise in genetic engineering of non-model microbial organisms. It is AbbVies policy to employ qualified persons of the greatest ability.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, Inc, ABBV, Cerevel, Abbvie, share, and the most common words in the summary are: abbvie, stock, market, job, new, open, news, . One of the sentences in the summary was: AbbVie currently Up 11 Consecutive Days, on Pace for Longest Winning Streak since December 2021.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #job #new #open #news.